Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Camidanlumab Tesirine · ADCT-301

Antibody-drug conjugate · Cytotoxic, directed at CD25 (IL2RA) · developed by ADC Therapeutics

Phase 2 Most advanced trial (none active)

ADCT Developer

2 Registered trials

What is Camidanlumab Tesirine?

Camidanlumab tesirine is an antibody-drug conjugate comprising a human IgG1 monoclonal antibody against CD25 conjugated to a pyrrolobenzodiazepine dimer. The antibody binds CD25 on tumor cells, triggering internalization and release of the cytotoxic payload, which cross-links DNA and inhibits replication. It is studied in relapsed or refractory Hodgkin lymphoma, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ADCT-301
Drug type: Antibody-drug conjugate
Targets: CD25 (IL2RA)
Mechanism: Cytotoxic, directed at CD25 (IL2RA)
Pathways: DNA replication inhibition, interstrand DNA cross-linking
Therapy area: Oncology
Developer: ADC Therapeutics S.A. (ADCT)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: LYJ1AEJ9YH

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04639024	Phase 2	Acute Myeloid Leukemia (AML)	Terminated	ADCT
NCT04052997	Phase 2	Relapsed Hodgkin Lymphoma	Completed	ADCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Myeloproliferative Neoplasm (MDS/MPN)Refractory Hodgkin LymphomaRelapsed Hodgkin Lymphoma

Other drugs acting on IL2RA

Aldesleukin FDA approved Anti-Thymocyte Globulin FDA approved Denileukin Diftitox FDA approved IOV-3001 Phase 1/2

More from ADC Therapeutics

Loncastuximab tesirine FDA approved ADCT-502 Phase 1 Mipasetamab Uzoptirine Phase 1 Olintatug Tesirine Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ADCT page.

Follow ADCT, the company behind Camidanlumab Tesirine

See ADCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ADCT catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z